s 12024 profile

S 12024: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	132958
MeSH ID	M0228713

Synonyms (14)

Synonym
1-methyl-8-((morpholin-2-yl)methoxy)-1,2,3,4-tetrahydroquinoline monomethane sulfonate
596jg0w99x ,
quinoline, 1,2,3,4-tetrahydro-1-methyl-8-(2-morpholinylmethoxy)-, (s)-, monomethanesulfonate
152985-36-9
s-12024
unii-596jg0w99x
s 12024
quinoline, 1,2,3,4-tetrahydro-1-methyl-8-((2s)-2-morpholinylmethoxy)-, monomethanesulfonate, (s)-
dabelotine mesylate, (s)-
(+)-(s)-s-12024
DTXSID30934642
methanesulfonic acid--1-methyl-8-[(morpholin-2-yl)methoxy]-1,2,3,4-tetrahydroquinoline (1/1)
Q27261669
(s)-dabelotine mesylate

Research Excerpts

Overview

S 12024-2 is a new drug in phase II development that possesses cognitive enhancing properties.

Excerpt	Reference	Relevance
"S 12024-2 is a new drug in phase II development that possesses cognitive enhancing properties. "	( Determination of S 12024 enantiomers in human plasma by liquid chromatography after chiral pre-column derivatization. Baune, A; Boursier-Neyret, C; Castagne, I; Klippert, P; Sauveur, C, )	1.91

Pharmacokinetics

Excerpt	Reference	Relevance
"Steady-state concentrations of S12024, a novel compound for treatment of Alzheimer's disease, were studied to determine the pharmacokinetic parameters of S12024 in Phase IIa patients and to assess the effect of patient characteristics on those pharmacokinetics."	( Application of population pharmacokinetics to the phase II development of an anti-Alzheimer's disease compound, S12024. Jochemsen, R; Lachaud-Pettiti, V; Laveille, C; Neuman, E, 1998)	0.3

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	6 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.05 (24.57)
Research Supply Index	2.40 (2.92)
Research Growth Index	4.45 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.05)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (42.86%)	5.53%
Reviews	1 (14.29%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	3 (42.86%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
amyloid beta-peptides amyloid beta-protein (1-28): binding of synthetic beta-amyloid peptide fragments to glycosaminoglycan is pH-dependent	1.99	1	0

Condition	Relationship Strength	Studies	Trials
Acute Confusional Senile Dementia [description not available]	6.13	4	3
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	6.13	4	3
Degenerative Diseases, Central Nervous System [description not available]	1.99	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	1.99	1	0
Neurodegenerative Diseases Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.	1.99	1	0
Cognition Disorders Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.	3.38	1	1

s 12024

Description